Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: An open-label study

American Journal of Clinical Dermatology

Volumn 9, Issue 2, 2008, Pages 105-109

  Varma, Rajat ^a,b   Cafardi, Jennifer A ^a   Cantrell, Wendy ^a   Elmets, Craig ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Efalizumab, therapeutic use; Psoriasis, treatment

Indexed keywords

EFALIZUMAB;

ADULT; ANKLE INJURY; ARTICLE; BACKACHE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL OTITIS; FEMALE; FEVER; FOOT DISEASE; HAND DISEASE; HEADACHE; HERPES ZOSTER; HUMAN; MALAISE; MALE; MYALGIA; NAUSEA; PARESTHESIA; PATIENT ATTITUDE; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RHINORRHEA; SCORING SYSTEM; SINUSITIS; TINNITUS; ULCERATIVE COLITIS; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOOT; HAND; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RECURRENCE; SKIN; TREATMENT OUTCOME;

EID: 39549115899     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809020-00003     Document Type: Article

References (17)

1. De Korte J, Sprangers MA, Mombers FM, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004 Mar; 9 (2): 140-7
2. Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003 Aug; 49 (2): 271-5
3. Forman AB, Roenigk Jr HH, Caro WA, et al. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989 Apr; 125 (4): 515-9
4. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999 Jul; 141 (1): 108-12
5. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290 (23): 3073-80
6. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13
7. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005 Mar; 52 (3 Pt 1): 425-33
8. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8
9. Fretzin S, Crowley J, Jones L, et al. Successful treatment of hand and foot psoriasis with efalizumab therapy. J Drugs Dermatol 2006 Oct; 5 (9): 838-46
10. Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis 2006 Sep; 78 (3): 178-80
11. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 2003 Nov; 72 (5): 396-8
12. Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007 Mar; 23 (2): 176-9
13. Cohen DJ, Fivenson D, Kimball AB, et al. Safety and tolerability of efalizumab therapy: a phase IIIb open-label study including patients using concurrent topical or phototherapy or recently transitioning from nonbiologic systemic psoriasis therapies. Presented at the 63rd annual meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA)
14. Michaelsson G, Kajermo U, Michaelsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005 Dec; 153 (6): 1243-4
15. Roux CH, Brocq O, Leccia N, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol 2007 Feb; 34 (2): 434-7
16. Jullien D, Prinz JC, Langley RGB, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 2004; 208: 297-306
17. Leonardi CL, Caro I, Sofen H, et al. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaque psoriasis [poster no. 532]. Presented at the American Academy of Dermatology annual meeting; 2007 Feb 2-6; Washington, DC